Atacicept Uses, Dosage, Side Effects and Interactions
Trutakna
Trutakna was the first atacicept product the FDA approved, in 2026.
Atacicept is a once-weekly injected medicine that reduces protein leaking into the urine in adults with primary IgA nephropathy (a kidney disease) who are at risk of it getting worse.
Quick links
Ask Anything About AtaciceptType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Atacicept in Short
What it treatsAtacicept, sold as Trutakna, is used to reduce proteinuria (protein in the urine) in adults with primary immunoglobulin A nephropathy (IgAN). It is for people whose disease is at risk of progressing. This use is approved under accelerated approval, based on reduced proteinuria.
- How you get it Prescription only
- Comes asInjection (under the skin)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
The Pharmacist’s Take
Trutakna (atacicept) is a specialist medicine that lowers protein in the urine of adults with primary IgA nephropathy, a kidney disease, by blocking BAFF and APRIL, two immune signals that drive the abnormal IgA behind it; it has been on the U.S. market only since about 2026, with no generic version. It is generally well tolerated, and what people notice most is redness or soreness at the injection spot and colds. Infection is the main risk, since it dampens antibody production, so call your doctor for a fever or worsening symptoms. It was approved for lowering urine protein, and its long-term effect on kidney function is still being confirmed.
Key Takeaways From the HelloPharmacist Team
- Inject it under the skin once a week with the autoinjector, something you or a caregiver can do at home.
- Expect an infection check before your first dose, and starting waits if you have an active infection.
- Get your recommended vaccines before starting, skip live vaccines from 30 days before through treatment, and ask before any new vaccine.
- Tell your prescriber if you also take a steroid such as prednisone, since stacking immune-dampening medicines raises infection risk.
Patient Information Guide for Atacicept
What It’s Used For
Atacicept is used for one kidney condition.
- Trutakna (subcutaneous injection) reduces proteinuria in adults with primary IgA nephropathy who are at risk for disease progression.
- This is an accelerated approval based on reduced proteinuria. Whether it slows long-term kidney function decline has not been established.
How It Works
Atacicept is a fusion protein that binds and blocks BAFF (also called BLyS) and APRIL. These are immune signals that help drive production of galactose-deficient IgA1 (Gd-IgA1), which is involved in IgA nephropathy. Blocking them lowers Gd-IgA1 levels.
Dosage
Trutakna is given as a subcutaneous injection once a week with an autoinjector, at home by you or a caregiver.
- If you miss a dose, take it as soon as possible. Then go back to weekly dosing, counting one week from the missed dose.
- Let the autoinjector sit at room temperature for 15 to 30 minutes first. Do not heat it.
- If needed, it can be kept at room temperature for a single period of up to 3 days. Do not put it back in the fridge, and discard it if not used in that time.
- The liquid should be clear to slightly opalescent and brownish-yellow.
- Rotate sites, such as the abdomen and thigh.
Follow your prescriber's directions and the Instructions for Use.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Protein in the urine from IgA nephropathy (a kidney disease)
For adults
Usual dose 150 mg once a week
- 150 mg injected subcutaneously (SC) once weekly
Good to know
If a dose is missed, administer the missed dose as soon as possible and then resume once weekly dosing, one week from administration of the missed dose
Side Effects
The most common side effects in studies were:
Common side effects
- Injection site reactions
- Redness at the injection site
- Upper respiratory tract infection (cold-like infection)
- Infections in general
When to get medical help
- Call your doctor if you develop signs of infection, such as fever or symptoms that are getting worse. Your doctor may pause treatment if an infection becomes serious.
- Get medical help right away for signs of a serious allergic reaction to the medicine.
- Tell your doctor before getting any vaccine while on treatment.
Most were mild or moderate and cleared without stopping treatment. Call your doctor about any serious infection or signs of allergic reaction.
Warnings and Precautions
- Infection risk: Atacicept suppresses the immune system. Treatment should be delayed during an active infection, and your doctor may pause it if a serious infection develops.
- Vaccines: It may weaken vaccine responses. Live vaccines are not recommended within 30 days before starting or during treatment.
- Other immune drugs: Combining it with drugs that affect the immune system, such as systemic corticosteroids, may increase infection risk.
Interactions
The label's main cautions involve drugs that affect the immune system and vaccines.
- Systemic corticosteroids and other immune-affecting drugs: may increase infection risk.
- Other immune-modulating therapies: use together has not been evaluated.
- Live vaccines: not recommended, because safety together has not been established.
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use with a prior serious allergic reaction to atacicept-vymj or its ingredients.
- Tell your doctor about any current, chronic or recurring infections.
- Complete recommended vaccines before starting.
- Pregnancy: data are insufficient, and the baby's immune system could be suppressed. Pregnant women exposed can report to 1-833-633-8372.
- Breastfeeding: no data are available, so weigh the benefits and risks with your doctor.
- Children: not established.
- Adults 65 and over: too few were studied to compare, though drug levels were similar.
Half-Life and How Your Body Processes It
After an injection under the skin, blood levels peak in about 36 hours. Steady levels take about 24 weeks of weekly dosing. Atacicept is a protein, so the body is expected to break it down into small peptides and amino acids. Its half-life is about 40 days. Age, sex, weight, race and mild to severe kidney impairment did not cause clinically significant differences in drug levels.
Storage
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Stored at room temperature up to 25°C (77°F), for a single period of 3 days (72 hours). Stored at room temperature, it should not be placed back into the refrigerator.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Atacicept: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Atacicept — the kind of thing our pharmacy team would talk through with you at the counter.
What is atacicept (Trutakna) used for?
What happens if I miss a dose of atacicept?
How do I store and inject Trutakna?
What side effects should I expect?
Can I get vaccines while taking atacicept?
Is atacicept safe in pregnancy?
Is atacicept available over the counter?
When was atacicept first available?
What is the brand name of atacicept?
What is the generic name of Trutakna?
What strengths does atacicept come in?
Is there a atacicept shortage?
Where can I read the atacicept prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Atacicept
Skip the scrolling. Ask in your own words and get an answer from Atacicept’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Atacicept’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Atacicept on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Atacicept Forms and Strengths (How It Comes)
Atacicept comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Atacicept inactive ingredients by manufacturer.
Injection
How this form is used
- Trutakna is used to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
- Trutakna is injected under the skin once a week using an autoinjector, which patients or caregivers can use at home.
- Trutakna should sit at room temperature for 15 to 30 minutes before injecting. Do not heat it.
- Use a different injection site each time. Trutakna can be injected in the abdomen or thigh.
- Do not use Trutakna if the liquid has particles or looks cloudy.
Atacicept on the U.S. Market: Products, Makers and Brands
How Atacicept appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Atacicept product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 2026. The one brand name in the directory today is Trutakna; the rest are generics.
Compare Atacicept Products
A representative set of FDA-listed product records for Atacicept — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 150 mg | Subcutaneous | Vera Therapeutics, Inc | BLA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Atacicept NDCs →
Atacicept Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Atacicept — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Atacicept are blood immunoglobulin g decreased, bedridden, burning sensation; about 100% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Atacicept in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Atacicept FDA Approval History
How Atacicept went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Atacicept was first approved by the FDA in 2026 (Brand: TRUTAKNA · Vera Therapeutics Inc.). It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Atacicept Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Atacicept recalls since July 2021.
✅No Atacicept recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Atacicept in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 1
- Forms in current FDA listings
- 1 of 1
RxCUI 2747209 -
Dose form (SCDF) Auto-InjectorIn current FDA listings
RxCUI 2747234Its strength (SCD)-
1 mL atacicept-vymj 150 mg/mL
RxCUI 2747237
-
1 mL atacicept-vymj 150 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Atacicept Supply and Shortage Status
Whether Atacicept is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Atacicept Brand Names
Atacicept has one brand name on record: Trutakna. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Atacicept: Manufacturers and Labelers
One company lists Atacicept products with the FDA. By number of product records, the largest are Vera Therapeutics, Inc. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Atacicept Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Vera Therapeutics, Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →